M A Richard1, S Aractingi2, P Joly3, E Mahé4, P Auquier5, S Le Guen6, C Acquadro7, F Boucher7, R J G Chalmers8. 1. EA 3279, département de dermatologie, centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix-Marseille université, hôpital de La Timone, Assistance publique-hôpitaux de Marseille, 13385 Marseille, France. Electronic address: mariealeth.richard@ap-hm.fr. 2. Dermatologie, hôpital Cochin-Tarnier, 89, rue d'Assas, 75006 Paris, France. 3. Service de dermatologie, CHU de Charles Nicolle, université de Normandie, 76000 Rouen, France. 4. Dermatologie, hôpital Victor Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100 Argenteuil, France. 5. EA 3279, centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix-Marseille université, 13385 Marseille, France. 6. R&D, Novartis pharma SAS, 92506 Rueil-Malmaison, France. 7. Languages services, Mapi, an ICON plc Company, 69000 Lyon, France. 8. Centre for Dermatology, University of Manchester, Manchester, Royaume-Uni.
Abstract
OBJECTIVE: Although several scores exist to assess psoriasis severity, most have marked limitations that rule out their use in routine clinical practice. A new score, the Simplified Psoriasis Index (SPI), has recently been developed and validated in adults in Britain for such use. It has separate components for current severity (SPI-s), psychosocial impact (SPI-p) and past history and interventions (SPI-p), and it is suitable for either professional assessment or patient self-assessment. The aim of this work was to produce a validated translation of SPI into French (as spoken in France). METHODS: The index was translated and validated using a strict methodology comprising respectively five and eight phases for the professional (proSPI) and self-administered instruments (saSPI). Translation of the saSPI instrument also involved a cognitive debriefing with five psoriasis patients. RESULTS: Linguistic discrepancies and subtle differences of meaning arising during the process were closely examined. The developer of the instrument ensured conceptual accuracy. A panel of health experts guaranteed that medical terms were correctly translated. Five patients with plaque psoriasis (two female and three male of median age 45 years [range: 31-78]) tested the SPI-p version during cognitive interviews and found the questionnaire clear and easy to understand. CONCLUSION: Validated French translations of both SPI instruments are now available for use in routine clinical practice. Further investigations are currently underway to validate the psychometric properties of the instrument.
OBJECTIVE: Although several scores exist to assess psoriasis severity, most have marked limitations that rule out their use in routine clinical practice. A new score, the Simplified Psoriasis Index (SPI), has recently been developed and validated in adults in Britain for such use. It has separate components for current severity (SPI-s), psychosocial impact (SPI-p) and past history and interventions (SPI-p), and it is suitable for either professional assessment or patient self-assessment. The aim of this work was to produce a validated translation of SPI into French (as spoken in France). METHODS: The index was translated and validated using a strict methodology comprising respectively five and eight phases for the professional (proSPI) and self-administered instruments (saSPI). Translation of the saSPI instrument also involved a cognitive debriefing with five psoriasispatients. RESULTS: Linguistic discrepancies and subtle differences of meaning arising during the process were closely examined. The developer of the instrument ensured conceptual accuracy. A panel of health experts guaranteed that medical terms were correctly translated. Five patients with plaque psoriasis (two female and three male of median age 45 years [range: 31-78]) tested the SPI-p version during cognitive interviews and found the questionnaire clear and easy to understand. CONCLUSION: Validated French translations of both SPI instruments are now available for use in routine clinical practice. Further investigations are currently underway to validate the psychometric properties of the instrument.
Authors: M-A Richard; J-P Lacour; M-P Konstantinou; M Ruer-Mulard; P Joly; S Aractingi; P Auquier; B Pelvet; M L Augustin; E Mahé; R J G Chalmers Journal: J Eur Acad Dermatol Venereol Date: 2020-10-02 Impact factor: 6.166